Literature DB >> 26060313

Empirical inference of circuitry and plasticity in a kinase signaling network.

Edmund H Wilkes1, Camille Terfve2, John G Gribben1, Julio Saez-Rodriguez2, Pedro Rodriguez Cutillas3.   

Abstract

Our understanding of physiology and disease is hampered by the difficulty of measuring the circuitry and plasticity of signaling networks that regulate cell biology, and how these relate to phenotypes. Here, using mass spectrometry-based phosphoproteomics, we systematically characterized the topology of a network comprising the PI3K/Akt/mTOR and MEK/ERK signaling axes and confirmed its biological relevance by assessing its dynamics upon EGF and IGF1 stimulation. Measuring the activity of this network in models of acquired drug resistance revealed that cells chronically treated with PI3K or mTORC1/2 inhibitors differed in the way their networks were remodeled. Unexpectedly, we also observed a degree of heterogeneity in the network state between cells resistant to the same inhibitor, indicating that even identical and carefully controlled experimental conditions can give rise to the evolution of distinct kinase network statuses. These data suggest that the initial conditions of the system do not necessarily determine the mechanism by which cancer cells become resistant to PI3K/mTOR targeted therapies. The patterns of signaling network activity observed in the resistant cells mirrored the patterns of response to several drug combination treatments, suggesting that the activity of the defined signaling network truly reflected the evolved phenotypic diversity.

Entities:  

Keywords:  MEK; PI3K; phosphoproteomics; signaling network; systems biology

Mesh:

Substances:

Year:  2015        PMID: 26060313      PMCID: PMC4485132          DOI: 10.1073/pnas.1423344112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Functional discovery via a compendium of expression profiles.

Authors:  T R Hughes; M J Marton; A R Jones; C J Roberts; R Stoughton; C D Armour; H A Bennett; E Coffey; H Dai; Y D He; M J Kidd; A M King; M R Meyer; D Slade; P Y Lum; S B Stepaniants; D D Shoemaker; D Gachotte; K Chakraburtty; J Simon; M Bard; S H Friend
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

Review 2.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

3.  Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Authors:  Alexey Goltsov; Dana Faratian; Simon P Langdon; James Bown; Igor Goryanin; David J Harrison
Journal:  Cell Signal       Date:  2010-10-14       Impact factor: 4.315

4.  Untangling the wires: a strategy to trace functional interactions in signaling and gene networks.

Authors:  Boris N Kholodenko; Anatoly Kiyatkin; Frank J Bruggeman; Eduardo Sontag; Hans V Westerhoff; Jan B Hoek
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

5.  Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors:  Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

6.  Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.

Authors:  Maria P Alcolea; Pedro Casado; Juan-Carlos Rodríguez-Prados; Bart Vanhaesebroeck; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2012-04-29       Impact factor: 5.911

7.  The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.

Authors:  V Munugalavadla; S Mariathasan; D Slaga; C Du; L Berry; G Del Rosario; Y Yan; M Boe; L Sun; L S Friedman; M Chesi; P Leif Bergsagel; A Ebens
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 8.  What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.

Authors:  Samuel J Klempner; Andrea P Myers; Lewis C Cantley
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

9.  A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes.

Authors:  B Dutta; L Pusztai; Y Qi; F André; V Lazar; G Bianchini; N Ueno; R Agarwal; B Wang; C Y Shiang; G N Hortobagyi; G B Mills; W F Symmans; G Balázsi
Journal:  Br J Cancer       Date:  2012-02-16       Impact factor: 7.640

10.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Authors:  Juan M García-Martínez; Jennifer Moran; Rosemary G Clarke; Alex Gray; Sabina C Cosulich; Christine M Chresta; Dario R Alessi
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

View more
  30 in total

1.  An Integrative Analysis of Tumor Proteomic and Phosphoproteomic Profiles to Examine the Relationships Between Kinase Activity and Phosphorylation.

Authors:  Osama A Arshad; Vincent Danna; Vladislav A Petyuk; Paul D Piehowski; Tao Liu; Karin D Rodland; Jason E McDermott
Journal:  Mol Cell Proteomics       Date:  2019-06-21       Impact factor: 5.911

2.  Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway.

Authors:  Tujin Shi; Mario Niepel; Jason E McDermott; Yuqian Gao; Carrie D Nicora; William B Chrisler; Lye M Markillie; Vladislav A Petyuk; Richard D Smith; Karin D Rodland; Peter K Sorger; Wei-Jun Qian; H Steven Wiley
Journal:  Sci Signal       Date:  2016-07-12       Impact factor: 8.192

3.  Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Authors:  Martin Schwill; Rastislav Tamaskovic; Aaron S Gajadhar; Florian Kast; Forest M White; Andreas Plückthun
Journal:  Sci Signal       Date:  2019-01-22       Impact factor: 8.192

4.  LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition.

Authors:  Qingsong Hu; Chunlai Li; Shouyu Wang; Yajuan Li; Bo Wen; Yanyan Zhang; Ke Liang; Jun Yao; Youqiong Ye; Heidi Hsiao; Tina K Nguyen; Peter K Park; Sergey D Egranov; David H Hawke; Jeffrey R Marks; Leng Han; Mien-Chie Hung; Bing Zhang; Chunru Lin; Liuqing Yang
Journal:  Cell Res       Date:  2019-01-10       Impact factor: 25.617

Review 5.  Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Authors:  Aik-Choon Tan; Simon Vyse; Paul H Huang
Journal:  Drug Discov Today       Date:  2016-07-21       Impact factor: 7.851

6.  Role for ERK1/2-dependent activation of FCHSD2 in cancer cell-selective regulation of clathrin-mediated endocytosis.

Authors:  Guan-Yu Xiao; Aparna Mohanakrishnan; Sandra L Schmid
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-24       Impact factor: 11.205

7.  Large-scale models of signal propagation in human cells derived from discovery phosphoproteomic data.

Authors:  Camille D A Terfve; Edmund H Wilkes; Pedro Casado; Pedro R Cutillas; Julio Saez-Rodriguez
Journal:  Nat Commun       Date:  2015-09-10       Impact factor: 14.919

8.  Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring.

Authors:  Maruan Hijazi; Ryan Smith; Vinothini Rajeeve; Conrad Bessant; Pedro R Cutillas
Journal:  Nat Biotechnol       Date:  2020-01-20       Impact factor: 54.908

9.  Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability.

Authors:  Edmund H Wilkes; Pedro Casado; Vinothini Rajeeve; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2017-07-03       Impact factor: 5.911

10.  Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells.

Authors:  Hagen Kulbe; Francesco Iorio; Probir Chakravarty; Carla S Milagre; Robert Moore; Richard G Thompson; Gemma Everitt; Monica Canosa; Alexander Montoya; Denis Drygin; Ioana Braicu; Jalid Sehouli; Julio Saez-Rodriguez; Pedro R Cutillas; Frances R Balkwill
Journal:  Oncotarget       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.